Trial Profile

A phase 2 clinical trial for the Treatment of the Symptoms of Neurodegenerative Diseases

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 21 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cannabidiol (Primary)
Indications Alzheimer's disease; Amyotrophic lateral sclerosis; Parkinson's disease
Focus Therapeutic Use
Acronyms NEUROBIS

Most Recent Events

24 Oct 2025 According to an Avextra media release, the 36-month clinical trial, authorized and funded by the Italian Ministry of Health (Ricerca Finalizzata 2022), will involve 180 patients with amyotrophic lateral sclerosis (ALS), Parkinson's disease, or Alzheimer's disease, and the first patient has already been enrolled.
24 Oct 2025 Status changed to recruiting.
14 Oct 2024 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com